These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20368556)

  • 21. The importance of test positive predictive value in ovarian cancer screening.
    Greene MH; Feng Z; Gail MH
    Clin Cancer Res; 2008 Nov; 14(22):7574; author reply 7577-9. PubMed ID: 18948386
    [No Abstract]   [Full Text] [Related]  

  • 22. The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
    Karlan BY; McIntosh M
    J Clin Oncol; 2007 Apr; 25(11):1303-4. PubMed ID: 17416848
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
    Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
    Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening and detection of ovarian cancer.
    Breedlove G; Busenhart C
    J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Increased level of carcinoembryonal antigen is not primarily a marker for ovarian cancer].
    Kristensen CA; Roed HM
    Ugeskr Laeger; 2005 Jan; 167(2):189; author reply 190. PubMed ID: 15697136
    [No Abstract]   [Full Text] [Related]  

  • 29. Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer.
    Senapad S; Neungton S; Thirapakawong C; Suphanit I; Hangsubcharoen M; Thamintorn K
    Anticancer Res; 2000; 20(2B):1297-300. PubMed ID: 10810438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
    Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].
    Lapchenkov VI; Dudarev AL; Vinokurov VL; Iurkova LE; Barbanel EIu
    Vestn Rentgenol Radiol; 1993; (5):30-1. PubMed ID: 7801580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
    Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
    Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic markers for ovarian cancer screening: not ready for routine clinical use.
    Coates RJ; Kolor K; Stewart SL; Richardson LC
    Clin Cancer Res; 2008 Nov; 14(22):7575-6; author reply 7577-9. PubMed ID: 18948387
    [No Abstract]   [Full Text] [Related]  

  • 35. Validation of serum biomarkers for detection of early-stage ovarian cancer.
    Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic markers for early detection of ovarian cancer.
    Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
    Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biomarker in gynecologic malignancies].
    Isonishi S
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mass-screening for ovarian cancer].
    Sato S; Higuchi T; Yokoyama Y; Sakamoto T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():601-4. PubMed ID: 15535316
    [No Abstract]   [Full Text] [Related]  

  • 40. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
    Petignat P; Vajda D; Obrist R
    Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.